Journal of Clinical & Experimental Pharmacology

División de Inmunología, Centro de Investigación Biomédica de Occidente, (CIBO-IMSS), Guadalajara, Jalisco, Mexico

Publications

• Research Article   
  Fulminant Hepatitis Managed with Pentoxifylline
  Author(s): Jiménez-Luévano MA, Ramírez-Flores S, Sepúlveda-Castro R, Jiménez-Partida AE, Jiménez-Partida MÁ, Ruiz-Mercado H, Cortés-Aguilar Y, Bravo-Cuellar A and Hernández-Flores G*
  
  Introduction: Fulminant hepatitis is a severe clinical entity that has a prevalence of 10/1,000,000, and its mortality can reach 80% of registered cases. Its etiology is multifactorial and does not respect gender, age, or socioeconomic or cultural levels. Transcription factor NF-κB, oxidative stress, proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 and growth factors play a fundamental role in this pathology. Treatment-of-choice is liver transplantation; however, the latter is far from being the ideal solution due to its accessibility and cost. Thus, we use the Pentoxifylline inhibitor of NF-κB and inflammatory and oxidative processes. Objective: To assess the response of patients with fulminant hepatitis using pentoxifylline. Methods: The four pediatric cases, diagnosed and classified wi.. View more»
  

  Abstract PDF